Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Sangamo Therapeutics, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Sangamo Therapeutics, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Davis Gregory D | Head of Research & Technology | 113,654 | May 27, 2026 | 7 |
| Jain Nikunj | Principal Accounting Officer | 235,292 | May 27, 2026 | 6 |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | 328,733 | May 27, 2026 | 7 |
| Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | 647,370 | May 27, 2026 | 6 |
| Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | 1,895,043 | May 27, 2026 | 6 |
| Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | 660,042 | Jan 26, 2026 | 3 |
| Parker H Stewart | Director | 112,600 | Jun 16, 2025 | 0 |
| Horn Margaret A | Director | 82,650 | Jun 16, 2025 | 0 |
| Meyers James R | Director | 99,600 | Jun 16, 2025 | 0 |
| Hillan Kenneth J. | Director | 99,600 | Jun 16, 2025 | 0 |
| Carey Robert | Director | 99,600 | Jun 16, 2025 | 0 |
| Smith Karen L. | Director | 102,100 | Jun 16, 2025 | 0 |
| Markels John | Director | 96,384 | Jun 16, 2025 | 0 |
| Beers Courtney | Director | 82,650 | Jun 16, 2025 | 0 |
| Pooler Amy | VP, HEAD OF RESEARCH | 193,923 | Aug 27, 2024 | 0 |
| McClung David Mark | EVP, Chief Operating Officer | 212,471 | Nov 28, 2023 | 0 |
| Fontenot Jason D. | SVP, Chief Scientific Officer | 136,270 | Nov 28, 2023 | 0 |
| Biogen Inc. | 10% Owner | 17,652,466Indirect | Sep 28, 2023 | 0 |
| Biogen MA Inc. | 10% Owner | 17,652,466Indirect | Sep 28, 2023 | 0 |
| Ramelmeier Rolf Andrew | EVP, Technical Operations | 171,467 | May 30, 2023 | 0 |
| Zakrzewski Joseph S | Director | 60,700 | Mar 1, 2022 | 0 |
| Ramasastry Saira | Director | 35,700 | Mar 1, 2022 | 0 |
| Schott Robert J. | SVP, Head of Development | 75,537 | Mar 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 (view filing)4:07 PM ET | Apr 22 | 1 day | Davis Gregory DHead of Research & Technology | SSale | −69.8K | $0.2534 | −$17.7K | −37.7%115.3K after | |
| Apr 23, 2026 (view filing)4:05 PM ET | Apr 21 | 2 days | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | SSale | −345.9K | $0.2578 | −$89.2K | −51.0%332.8K after | |
| Sep 28, 2023 (view filing)5:30 PM ET | Sep 26 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −6.00M | $0.50 | −$3.00M | −25.4%17.7M after | |
| Aug 31, 2022 (view filing)7:03 PM ET | Aug 29-30 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −500.0K | $5.31 | −$2.66M | −2.1%23.7M after | 2 lots |
| Jun 6, 2022 (view filing) | Jun 3 | 3 days | Markels JohnDirector | PPurchase | +6.78K | $3.69 | +$25.0K | +26.4%32.5K after | |
| Jun 3, 2022 (view filing) | Jun 1 | 2 days | Parker H StewartDirector | PPurchase | +5.00K | $3.60 | +$18.0K | +11.4%48.7K after | |
| Dec 30, 2021 (view filing)5:12 PM ET | Dec 28 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −2.76K | $8.51 | −$23.5K | 0.0%24.2M after | |
| Dec 28, 2021 (view filing)8:11 AM ET | Dec 23-27 | 5 days | Biogen Inc. and 1 other10% Owner | SSale | −81.8K | $8.55 | −$699.7K | −0.3%24.2M after | 2 lots |
| Dec 10, 2021 (view filing)4:08 PM ET | Dec 9 | 1 day | Biogen Inc. and 1 other10% Owner | SSale | −23.7K | $8.56 | −$202.5K | −0.1%24.2M after | |
| Dec 9, 2021 (view filing)4:08 PM ET | Dec 7-8 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −128.0K | $8.59 | −$1.10M | −0.5%24.3M after | 2 lots |
| Dec 3, 2021 (view filing)4:09 PM ET | Dec 1-2 | 2 days | Biogen Inc. and 1 other10% Owner | SSale | −2.60K | $8.51 | −$22.2K | 0.0%24.4M after | 2 lots |
| Nov 30, 2021 (view filing)4:20 PM ET | Nov 26 | 4 days | Biogen Inc. and 1 other10% Owner | SSale | −28.9K | $8.60 | −$248.4K | −0.1%24.4M after |